Citation Impact
Citing Papers
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
2013
De novoisolation of antibodies with pH-dependent binding properties
2015
Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections
2008
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
2008
Interaction of Silymarin Flavonolignans with Organic Anion-Transporting Polypeptides
2013
Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness
2008 Standout
Clinical Pharmacokinetics of Metformin
2011
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
2012
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
2020 Standout
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing
2012 StandoutNobel
The mechanisms of action of metformin
2017 Standout
Severe Sepsis and Septic Shock
2013 Standout
Fruit juice inhibition of uptake transport: a new type of food–drug interaction
2010
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
2020 Standout
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections
2010
Small-Molecule Library Screening by Docking with PyRx
2014 Standout
Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro
2010
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly
2008
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
2013 StandoutNobel
Chemical predictive modelling to improve compound quality
2013
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Antiviral combinations for severe influenza
2014
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response
2016 StandoutNobel
Type 2 diabetes mellitus
2015 Standout
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
2010
Aliskiren: the first renin inhibitor for clinical treatment
2008
Glycaemic control in type 2 diabetes: Targets and new therapies
2009
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
The use of antiviral agents for the management of severe influenza
2010
Fingerprinting food: current technologies for the detection of food adulteration and contamination
2012 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
2009 Standout
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
2015 Standout
Review: Update on Newer Antihypertensive Medicines and Interventions
2010
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem
2014 Standout
Clinical Practice Guideline: Tonsillectomy in Children
2010 Standout
Update on Avian Influenza A (H5N1) Virus Infection in Humans
2008
Green synthesis of zinc oxide nanoparticles using Hibiscus subdariffa leaf extract: effect of temperature on synthesis, anti-bacterial activity and anti-diabetic activity
2014 Standout
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Direct Renin Inhibitors as a New Therapy for Hypertension
2010
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Catalytic Asymmetric Protonation of Silyl Ketene Imines
2013 StandoutNobel
Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro
2009
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
2015 Standout
Works of Dan Howard being referenced
Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren
2008
The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers
2007
Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers
2007
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
2008
Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects
2007
Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects
2008
Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects
2007
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
2007
Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers
2007
Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia
2005
A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination
2007
Pharmacokinetics of the Oral Direct??Renin Inhibitor Aliskiren Alone and??in Combination with Irbesartan in??Renal Impairment
2007
Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren
2008
Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis
2013
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects
2008
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
2007